Menu
  • About us
  • Our partners
  • Careers
  • News & events
  • Publications, posters and patents
  • Contact us
  • About us
  • Our partners
  • Careers
  • News & events
  • Publications, posters and patents
  • Contact us
Search
BioFocus
Accelerating Drug Discovery
Tel: +44 1799 533500
  • Home
  • Drug discovery capabilities
  • Therapeutic area expertise
  • Academic Engagement
In this section
  • News
  • Events
  • Webinars
  • Newsletters
  • Register

Archive

  • 2013
    • BioFocus launches Academic Engagement initiative
    • BioFocus extends its collaboration with The Michael J. Fox Foundation
    • Peter Rehse joins BioFocus as Senior Director, Structural Biology
    • BioFocus expands ion channel offering through agreement with ChanTest
  • 2012
    • BioFocus achieves milestone in its drug discovery collaboration with UCB
    • Activiomics signs research agreement with Kyowa Hakko Kirin as part of its strategic partnership with BioFocus
    • Galapagos subsidiary BioFocus and Ono sign a drug discovery agreement in the Field of CNS Disorders
    • BioFocus expands its drug discovery offering with proteomics technology from Activiomics
    • BioFocus selects Titian’s Mosaic™ software to provide optimized screening services
    • Ono and Galapagos subsidiary BioFocus sign an additional target discovery agreement in the field of allergic disease
    • BioFocus and Argenta announce drug discovery collaboration with AstraZeneca in respiratory and inflammatory disease
    • Almirall and BioFocus enter research alliance
  • 2011
    • BioFocus creates novel diverse screening library
    • Almirall and BioFocus announce collaboration to find new hit compounds against key targets
    • BioFocus announces second extension to collaboration with Chiesi
    • Argenta and BioFocus announce two-year extension of drug discovery collaboration with Genentech
    • BioFocus and InterMed Discovery announce Marketing Collaboration
    • BioFocus enters collaboration with Michael J. Fox Foundation
    • BioFocus extends collaboration with Usher III Initiative
    • Evotec acquires compound management business from Galapagos
    • Astellas Pharma and BioFocus sign target discovery agreement
    • BioFocus delivers validated oncology targets to Janssen
    • BioFocus and Almac collaborate to offer fluorescent lifetime assays
    • University of Nottingham and BioFocus sign compound management agreement
    • BioFocus leads compound library market with innovative business model
    • Lundbeck Research USA, Inc. and BioFocus sign compound management agreement
    • Ono and Galapagos subsidiary BioFocus sign target discovery agreement in the field of autoimmune disease
  • 2010
    • BioFocus extends collaboration with Amgen into 2012
    • BioFocus extends collaboration with Chiesi
    • BioFocus and the National Cancer Institute sign compound management agreement
    • BioFocus signs compound management agreement with eMolecules, Inc.
    • BioFocus launches new compound libraries
    • Argenta expands collaboration with Genentech to include BioFocus
    • BioFocus and Usher III Initiative, Inc. announce collaboration
    • BioFocus and University of Bristol enter drug discovery collaboration in chronic pain
    • NIH extends agreement with BioFocus until end 2012
    • BioFocus renouvelle son agrément CIR (Crédit Impôt Recherche)
    • BioFocus renews C.I.R. (French Research Tax Credit) accreditation
    • BioFocus and CHDI Foundation, Inc. enter new five-year collaboration for Huntington’s disease therapeutics
    • BioFocus launches four compound libraries targeting kinases and protein-protein interactions
    • Today, Galapagos announced the purchase of Argenta Discovery 2009 Ltd.
    • BioFocus achieves €1.6 M in payments
    • TB Alliance and BioFocus sign compound management agreement
  • 2009
    • Doris Hafenbradl joins BioFocus as Senior Director, Biology and Natural Products
    • BioFocus and DiscoveRx announce a co-marketing agreement for GPCR screening
    • BioFocus launches www.SilenceSelect.com microsite
    • BioFocus DPI announces expanded drug discovery collaboration with Schering-Plough
    • BioFocus DPI launches compound library targeting protein-protein interactions plus three new kinase libraries
    • BioFocus DPI and Procter & Gamble sign compound management agreement
    • BioFocus DPI and Oncodesign forge alliance to provide integrated oncology drug discovery services
    • Dates announced for free GPCR conference
    • Institute for OneWorld Health Announces Successful Collaboration to Fight Neglected Diarrheal Diseases in Developing Countries
    • BioFocus DPI launches six new SoftFocus libraries
    • BioFocus DPI to apply TET Technology in high-throughput screening campaigns
    • BioFocus DPI enhances high-throughput screening library
    • BioFocus DPI and Medicines for Malaria Venture collaborate to identify anti-malarial compounds
    • Royal Approval for Chesterford Research Park
    • BioFocus DPI enhances ADME/PK Laboratory bioanalytical capabilities
    • BioFocus DPI extends drug discovery collaboration with Lilly
    • BioFocus DPI enhances high-content screening capabilities
  • 2008
    • Galapagos extends drug discovery collaboration with Amgen into 2010
    • Scott Snyder to head BioFocus DPI Compound Management
    • BioFocus DPI and Dart Neuroscience LLC sign drug discovery and compound management agreements
    • Galapagos and Merck Serono enter new collaboration agreements
    • BioFocus DPI and ZoBio announce marketing agreement
    • Galapagos sells San Diego chemistry facility to ChemVentures
    • Galapagos and CHDI enter new collaboration agreements
    • Enhanced decision support software streamlines data access and integration
    • BioFocus DPI launches seven new libraries including its first libraries targeting proteases
    • Cutting-edge meeting on ion channel drug discovery
    • OneWorld Health and BioFocus DPI expand collaboration to develop new drugs for the treatment of childhood diarrheal diseases
    • BioFocus DPI adds structural biology to its drug discovery services
    • UCB transfers UK-based medicinal chemistry program to BioFocus DPI
    • BioFocus DPI transfers predictive drug discovery databases to EMBL’s European Bioinformatics Institute
    • NIH extends agreement with BioFocus DPI
    • Boehringer Ingelheim licenses drug targets from autoimmune collaboration with BioFocus DPI
    • BioFocus DPI signs new compound management agreement
    • California stem Cell and BioFocus DPI to collaborate in ALS Association-funded research using human motor neurons
    • BioFocus DPI to perform medicinal chemistry services for UCL research project
    • Galapagos and Allergan enter drug discovery collaboration
    • BioFocus DPI releases five new compound libraries
    • BioFocus DPI launches ‘Intelligent Screening’ platform at SBS
    • BioFocus DPI takes global license for Cresset’s molecular field software
    • BioFocus DPI to distribute NIH’s Clinical Compound Collection
    • BioFocus DPI launches ADME/PK service and software platform
    • Galapagos extends drug discovery collaboration with Lilly in nuclear hormone receptor research
    • Galapagos enters into oncology target discovery collaboration with Janssen Pharmaceutical
  • 2007
    • Galapagos and Cystic Fibrosis Foundation Therapeutics announce new drug discovery collaboration worth up to $8.1 million U.S. dollars
    • BioFocus DPI launches GPCR SARfari
    • BioFocus DPI enhances ADME optimization capabilities
    • BioFocus DPI launches five new compound libraries
    • Galapagos announces expanded relationship with AstraZeneca: BioFocus DPI to provide drug discovery services to US-site
    • Galapagos announces milestone in collaboration with Boehringer Ingelheim
    • BioFocus DPI launches Kinase SARfari knowledge base
    • Galapagos announces new collaboration agreements and a management appointment
    • Galapagos and AstraZeneca enter new drug discovery collaboration
    • Galapagos announces agreement worth up to €6.3 million with United States Environmental Protection Agency (EPA)
    • Galapagos signs two new drug discovery collaborations with Ono Pharmaceutical
    • Galapagos to supply chemical compound sets to Johnson & Johnson Pharmaceutical Research & Development, Division of Janssen Pharmaceutica NV
    • Galapagos and the University of Bristol enter drug discovery collaboration
    • Galapagos expands and extends drug discovery collaboration with Amgen into 2008
  • 2006
    • Galapagos and The ALS Association announce €2.4 million target discovery alliance
    • Galapagos to acquire Inpharmatica
    • Galapagos awarded European Union grant
    • Galapagos extends target discovery alliance with Cystic Fibrosis Foundation Therapeutics
    • Galapagos announces natural compounds collaboration with LEO Pharma
    • Inpharmatica develops target-family specific knowledge base for Schering AG
    • Galapagos and OneWorld Health collaborate to develop new drugs for the treatment of diarrheal diseases
    • Galapagos announces new collaboration with AstraZeneca
    • Galapagos and Cellzome in kinase drug discovery collaboration
    • Galapagos completes acquisition of drug discovery service operations of Discovery Partners International
    • Galapagos expands chemistry services through contracts with Indian companies
    • Galapagos announces exclusive agreement with Upstate for marketing and sales of adenovirus products
    • Galapagos and Arthrogen enter target discovery alliance
    • Galapagos enters a three-year collaboration with Roche
    • Galapagos and BASF extend research collaborations
    • Galapagos and Cancer Research Technology announce new anti-cancer drug discovery collaboration
    • Galapagos enters new collaboration in autoimmune discovery research
    • Angus MacLeaod named Director of Medicinal Chemistry at BioFocus
Contact us

News

Loading loading...
  • Page 1 of 15
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...
  • >>

  • BioFocus launches Academic Engagement initiative

    Wed 01 May 2013
    View press release >

  • BioFocus extends its collaboration with The Michael J. Fox Foundation

    Wed 17 Apr 2013
    View press release >

  • Peter Rehse joins BioFocus as Senior Director, Structural Biology

    Mon 11 Feb 2013
    View press release >

  • BioFocus expands ion channel offering through agreement with ChanTest

    Wed 06 Feb 2013
    View press release >

  • BioFocus achieves milestone in its drug discovery collaboration with UCB

    Tue 04 Dec 2012
    View press release >

  • Activiomics signs research agreement with Kyowa Hakko Kirin as part of its strategic partnership with BioFocus

    Thu 22 Nov 2012
    View press release >

  • Galapagos subsidiary BioFocus and Ono sign a drug discovery agreement in the Field of CNS Disorders

    Mon 03 Sep 2012
    View press release >

  • BioFocus expands its drug discovery offering with proteomics technology from Activiomics

    Wed 25 Jul 2012
    View press release >
Loading loading...
  • Page 1 of 15
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...
  • >>
Contact us

Our website uses cookies to offer the best possible experience. By continuing to use the site you are agreeing to our usage of cookies. Find out more >

  • Sign up to our mailing list
  • Follow us on Twitter
    • Hogan Ralph Lauren Outlet Borsa Louis Vuitton Abercrombie Milano Borse Burberry

BioFocus®, SoftFocus®, Galapagos®, SilenceSelect® and FLeXSelect® ThemePair™, FieldFocus™, HDRA™. Helical Domain Recognition Analysis™, 2D Roadmap™, Thematic Analysis™, SFK™, SFI™, SFG™ and PrimePath™ are trademarks of Galapagos NV and/or its affiliates.

  • Terms and conditions
  • Privacy policy
  • Sitemap